Department of Anaesthesiology, Erasmus Medical Centre, Rotterdam, The Netherlands.
Thorax. 2009 Nov;64(11):963-7. doi: 10.1136/thx.2009.116731. Epub 2009 Aug 30.
Chronic obstructive pulmonary disease (COPD) is associated with an increased risk of lung cancer, independently of smoking. However, the relationship between COPD and total cancer mortality is less certain. A study was undertaken to investigate the association between COPD and total cancer mortality and to determine whether the use of statins, which have been associated with cancer risk in other settings, modified this relationship.
The study included 3371 patients with peripheral arterial disease who underwent vascular surgery between 1990 and 2006; 1310 (39%) had COPD and the rest did not. The primary end point was cancer mortality (lung and extrapulmonary) over a median follow-up of 5 years.
COPD was associated with an increased risk of both lung cancer mortality (hazard ratio (HR) 2.06; 95% CI 1.32 to 3.20) and extrapulmonary cancer mortality (HR 1.43; 95% CI 1.06 to 1.94). The excess risk was mostly driven by patients with moderate and severe COPD. There was a trend towards a lower risk of cancer mortality among patients with COPD who used statins compared with patients with COPD who did not use statins (HR 0.57; 95% CI 0.32 to 1.01). Interestingly, the risk of extrapulmonary cancer mortality was lower among statin users with COPD (HR 0.49; 95% CI 0.24 to 0.99).
COPD was associated with increased lung and extrapulmonary cancer mortality in this large cohort of patients with peripheral arterial disease undergoing vascular surgery. The risk of lung cancer mortality increased with progression of COPD. Statins were associated with a reduced risk of extrapulmonary cancer mortality in patients with COPD.
慢性阻塞性肺疾病(COPD)与肺癌风险增加相关,且这种关联独立于吸烟。然而,COPD 与总癌症死亡率之间的关系尚不确定。本研究旨在调查 COPD 与总癌症死亡率之间的关系,并确定他汀类药物(在其他环境中与癌症风险相关)的使用是否会改变这种关系。
该研究纳入了 1990 年至 2006 年间接受血管手术的 3371 例外周动脉疾病患者;其中 1310 例(39%)患有 COPD,其余患者没有。主要终点是中位随访 5 年内的癌症死亡率(肺癌和肺外癌)。
COPD 与肺癌死亡率(危险比(HR)2.06;95%置信区间(CI)1.32 至 3.20)和肺外癌死亡率(HR 1.43;95%CI 1.06 至 1.94)均呈正相关。这种超额风险主要由中重度 COPD 患者驱动。与未使用他汀类药物的 COPD 患者相比,使用他汀类药物的 COPD 患者的癌症死亡率风险呈下降趋势(HR 0.57;95%CI 0.32 至 1.01)。有趣的是,COPD 合并使用他汀类药物患者的肺外癌死亡率风险较低(HR 0.49;95%CI 0.24 至 0.99)。
在接受血管手术的外周动脉疾病患者中,COPD 与肺癌和肺外癌死亡率增加相关。COPD 严重程度的增加与肺癌死亡率的增加相关。他汀类药物的使用与 COPD 患者的肺外癌死亡率降低相关。